The Spectrum of Familial Hypercholesterolemia (FH) in Saudi Arabia: Prime Time for Patient FH Registry
Faisal Alallaf1, #, *, Fatima Amanullah H.Nazar2, #, Majed Alnefaie3, Adel Almaymuni3, Omran Mohammed Rashidi3, Khalid Alhabib4, Fahad Alnouri5, Mohamed-Nabil Alama6, Mohammad Athar7, Zuhier Awan3, *
Identifiers and Pagination:Year: 2017
First Page: 66
Last Page: 75
Publisher Id: TOCMJ-11-66
Article History:Received Date: 16/11/2016
Revision Received Date: 27/04/2017
Acceptance Date: 17/05/2017
Electronic publication date: 26/07/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Familial hypercholesterolemia (FH) is a life-threatening inherited condition. Untreated patients have the risk to develop raised plasma levels of cholesterol, atherosclerosis and cardiovascular disease (CVD). If diagnosed and treated early in life, the pathological consequences due to atherosclerosis could be avoided and patients with FH can have an anticipated normal life. Mounting evidence suggests that FH is underdiagnosed and undertreated in all populations. The underlying molecular basis of FH is the presence of mutations in one or more genes in the low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB) or proprotein convertase subtilisin/kexin 9 (PCSK9). However, their prevalence is largely unknown in Saudi Arabia but given the high rates of consanguinity, the prevalence appears to be higher. Furthermore, the high prevalence of obesity and diabetes mellitus in Saudi Arabia increases the vascular disease burden in FH cases by adding additional CVD risk factors.
This article explores the spectrum of FH-causing mutations in the highly consanguineous Saudi community, the need for establishing the Saudi FH registry, the challenges in creating gene databases, and cascade screening.
The establishment of FH registry and genetic testing should raise awareness not only among healthcare professionals, but the general population as well. It also helps to provide the best treatment regimen in a cost effective manner to this under-recognised population of FH patients.
1. FAMILIAL HYPERCHOLESTEROLEMIA (FH)
FH is a monogenic disorder of lipid metabolism that plays a key role in developing cardiovascular disease (CVD). Affected individuals have isolated high serum cholesterol and low-density lipoprotein-cholesterol (LDL-C) levels (1). The disease is primarily inherited in an autosomal dominant (AD) manner, but it also has an autosomal recessive AR mode of inheritance. Genetic mutations in one or more genes could be the cause of FH. The established AD genes are: low-density lipoprotein receptor (LDLR) , apolipoprotein B-100 (APOB)  or proprotein convertase subtilisin/kexin type 9 (PCSK9) . Mutations in one allele of either of these genes may lead to the heterozygous FH (HeFH) phenotype and mutations in both alleles may lead to the more severe homozygous FH (HoFH) phenotype. The LDL receptor adaptor protein 1 (LDLRAP1) gene is responsible for the AR form of FH . The AR form of FH has clinical similarity to both HeFH and HoFH with intermediate LDL-C levels if both alleles are affected. However, a normal lipid profile is seen in parents, hence the AR pattern, and a greater response to lipid-lowering treatment are achieved in these patients .
Considering that molecular defects occur in two alleles of the gene locus, HoFH individuals normally show a conspicuously increased amount of total serum cholesterol (>500 mg/dL, 13 mmol/L) and LDL-C levels (>450 mg/dL, 11.7 mmol/L) . The accumulation of cholesterol leads to characteristic cutaneous lesions in the form of xanthoma tendinosum of the hands and feet, xanthelasmata around the eyelid and corneal arcus earlier in life [7, 8]. Myocardial infarction (MI) and sudden cardiac events can occur prematurely in adolescence due to atheroma of the coronaries, aortic root and valve . Patients with a null mutation of the LDLR gene, resulting in no protein product, have a higher susceptibility to CVD than those mutations that alter the gene sequence and partially disrupts LDL receptor function [8, 10]. In contrast, HeFH commonly presents with lower serum cholesterol (250-450 mg/dL or 6.5-11.6 mmol/L) and LDL-C (200-400 mg/dL or 5.2-10.4 mmol/L) levels than HoFH . They demonstrate the above clinical symptoms with slower progression of their disease. Patients with HeFH usually develop premature CVD before age 55 for men, and 60 for women. HeFH men tend to suffer from CVD than HeFH women probably due to sex-related hormonal factors .
2. CLINICAL AND LABORATORY DIAGNOSIS
Biochemical screening tests alone are not sufficient to confirm the presence of FH; this is due to the fact that cholesterol levels in the blood vary with several contributing factors such as, gender, age, ethnicity, certain drugs, physiological and pathological conditions. Indeed, the range of cholesterol values in FH cases overlap with non-genetic multifactorial hypercholesterolemia and may lead to a false negative or false positive diagnosis . There are at least 4 widely used diagnostic systems used for the diagnosis of FH; the Simon Broome Register Group (United Kingdom) , the Dutch Lipid Clinic Network (DLCN) , the Make Early Diagnosis to Prevent Early Deaths (MEDPED) criteria (USA) and the one released by the European Atherosclerosis Society . These diagnostic criteria rely mainly on; very high total cholesterol or LDL-C levels on repeated measurements. The Simon Broome and DLCN criteria, in addition to lipid parameters, take in consideration the presence of xanthomas, molecular diagnosis and a family history of some signs and symptoms of dyslipidaemia. Molecular genetic testing is based on direct DNA sequence analyses using a capillary method or high-throughput next-generation sequencing (NGS)-based method. Large insertions/deletions detection is usually done by the multiplex ligation-dependent probe amplification. Once a causative mutation is discovered in the index case, a cascade screening should be performed at least to the first degree relatives to demonstrate the dominant pattern of inheritance.
3. GENETICS OF FH
As mentioned earlier, mutations in one allele described above may lead to the HeFH phenotype while mutations in both alleles may lead to the HoFH phenotype. Few rare cases are ‘double heterozygotes’, i.e. they carry 2 different mutations of the aforementioned genes, which may lead to an intermediate phenotype between HeFH and HoFH . Compound heterozygous mutations cases can also occur due to different allelic variations on the same gene loci.
To further illustrate the complexity of FH genotype, only loss-of-function mutations in the LDLR and APOB genes and only gain-of-function mutations in the PCSK9 gene cause the disease. About 85% of FH cases are attributed to loss-of-function mutations in the LDLR gene . More than 1700 different mutations in the LDLR (p13.1-p13.3) gene have been described so far  and registered in online gene databases http://www.ucl.ac.uk/ldlr/Current . The LDLR database includes different types of mutations; single-nucleotide polymorphism, insertions/deletions, copy number variations and splicing sites defects. These mutations have the ability to disrupt the functional domains of the LDLR protein affecting its function to establish a normal initiative complex combining the receptor with the LDL-C particle.
Apolipoprotein B-100 (ApoB-100) is the ligand protein for the LDLR, encoded by the gene APOB that is mapped to the short arm of chromosome 2 (p24). APOB mutations account for <5% of FH cases . Defects in this protein result in ligand affinity reduction for the LDLR, which results in poor clearance of LDL-C from the circulation allowing for hypercholesterolemia independent of the LDLR activity .
In less than a decade, mutations in a third gene located on the short arm of chromosome 1 (p34.1-p32) have been identified to be responsible for nearly 1% of monogenic FH cases . The PCSK9 gene produces an enzyme used to be known as “neural apoptosis-regulated convertase 1”, which has been associated with the LDLR protein degradation in the lysosome thus preventing it from recycling . More than a handful of different gain-of-function mutations have been reported in the PCSK9 gene which can cause increased degradation of LDLRs, minimising the numbers of receptors on the cell surface and causing monogenic FH.
LDLRAP1 loss-of-function mutations result in a rare form of AR FH. The gene is mapped on the short arm of chromosome 1p35-36.1 . In addition, genome-wide association studies have shown a strong association between Apolipoprotein E (APOE) p.Leu167del and the AD hypercholesterolaemia phenotype in a large family. Awan et al.  reported a mutation in the APOE gene associated with the classical autosomal dominant hypercholesterolemia (ADH) phenotype from a proband of an Italian origin which confirmed the observation of Marduel et al. and suggesting APOE gene as the 4th locus in ADH . Other candidate genes have also been attributed to causing FH phenotype including ABCA1, APOA2, APOC3, PON2, APOC2 and LPL.
4. EPIDEMIOLOGICAL GENETICS OF FH
In most investigated Western populations, HeFH is perceived to affect approximately 1 in every 200 to 500 individuals  with an estimated one case in each million individuals for HoFH [26, 27]. However, recent studies have changed this perception and shown that FH is under diagnosed in most populations . The Copenhagen General Population Study, a sample from a random European general population, included 69,016 individuals with HeFH diagnosed using the DLCN criteria. This finding suggested that HeFH prevalence according to DLCN criteria may reach 1 in every 200 individuals , or, for molecularly defined HeFH, one in 244 . Consequently, HoFH may rise to one in every 300,000 individuals.
FH prevalence is greater with founder effects in geographically isolated regions, where the practice of consanguineous marriage increases the risk. Founder effects for FH were seen among French Canadians , Jews , South African Afrikaners , Lebanese , Indians , Tunisians , Icelanders  and Finns  among whom the frequency of LDLR mutations is higher than the general population. The Lebanese p.Cys681X mutation accounts for 82% of the FH cases in the Lebanese population . Remarkably, the frequency of HoFH cases is 10-fold higher in Lebanon than in neighbouring nations.
Up to date, there is no genetic epidemiological study conducted for the frequency of FH in Saudi Arabia. Based on the 2015 population census (http://www.stats.gov.sa/en/node, Accessed April 2017), the predicted prevalence of FH in Saudi Arabia is expected to range from 158,712 to 63,485 cases of HeFH, based on the rate of 1:200-500, and 53 to 106 cases of HoFH based on the rate of 1:300,000-600,000 Fig. (1). The data available for the prevalence of FH in Saudi Arabia is limited due to the lack of national registries and genetic screening for FH. Currently, >80 clinically and molecularly confirmed HoFH are being treated with LDL-apheresis every 2 weeks in a single centre in Riyadh (capital of Saudi Arabia) and another centre is being initiated to deal with the increasing demand for such service (personal communication), which supports the predicted numbers given Fig. (1).
5. SPECTRUM OF MUTATIONS CAUSING FH IN SAUDI ARABIA
Only a few reports on the molecular aspects of FH were related to Saudi individuals (38)(39)(40)(41)(42). A systematic review to collect all FH-related mutations reported in the Saudi populations resulted in 21 variants mapped to 3 genes; LDLR, APOB and PCSK9. As expected, the majority of these variants were in the LDLR gene (>80%) Fig. (2), and only 2 mutations among these were found to be novel variants in the LDLR gene; c.1332dup (p.D445*) (39) c.2026delG (p.G676Afs*33) (41) .
|Fig. (1). Estimated prevalence of Familial Hypercholesterolemia in Saudi Arabia. A. Expected Heterozygous Familial Hypercholesterolemia (HeFH) cases. B. Expected Homozygous Familial Hypercholesterolemia (HoFH) cases.|
|Fig. (2). Graphical representation of FH-related variations in the LDLR gene reported from the Saudi population.|
On the basis of several studies, one should expect to find APOB and PCSK9 variant in a smaller percentage of FH Saudi patients. Variation in the PCSK9 gene was found to be the second most common and variation in APOB gene were among the least common (Unpublished data; Dr Faisal Alallaf, Umm Al-Qura University: Medical genetic laboratories). No evidence of large deletions or duplications in the LDLR gene were associated with the presence of FH disease nor FH-related LDLRAP1 or APOE mutations were found.
From our clinical and molecular observation of FH cases, founder mutations were expected to originate from certain tribes in the central, northern and western region of Saudi Arabia .
The expected high prevalence of FH predicted from the high number of treated HoFH in Saudi Arabia, emphasise the urgent need for an FH registry as a preventive measure toward decreasing the number of HoFH. Indeed, both consanguineous and non-consanguineous high-risk individuals should be advised to have counselling and a genetic testing before having offspring and an immediate screening should be done for those children whom parents are clinically and molecularly confirmed FH cases.
6. MANAGEMENT OF FH
In contrast with secondary hypercholesterolemia, primary FH does not usually respond to diet. However, diet low in saturated fat is an important part of the management of FH together with lifestyle modification and smoking cessation. A common pharmacological strategy would be to combine statin-based treatment with other lipid-lowering medications with a different mechanism. For example, a statin might be combined with a cholesterol absorption inhibitor or a bile acid sequestrant which both work in the intestine to prevent cholesterol absorption [44, 45]. The FDA also approved PCSK9 inhibitor antibodies, neutralising circulating PCSK9, a protein associated with LDLR degradation in the liver for the treatment of FH patients . These monoclonal antibodies are not expected to work in HoFH with LDLR null-mutations, given the mode of action of PCSK9 on the LDLR protein which requires a functional LDLR. LDL apheresis (or lipoprotein apheresis) can be used in all mutations causing HoFH as well as severe HeFH and pregnant FH patients. This bimonthly or monthly dialysis-like procedure clears the blood from excess lipoprotein. Apheresis treatment duration lasts between 2 to 3h and usually reduces the LDL-C level by about 70% . Unfortunately, LDL particles increase over time, therefore, repeated treatment is required. At the present time, there is only 1 active LDL-apheresis centre in Saudi Arabia.
Recently, microsomal triglyceride transfer protein (MTP) inhibitors (lomitapide) and oligonucleotide developed against Apo-B 100 mRNA (mipomersen), have been approved in some countries for HoFH treatment . However, the effectiveness of aforementioned drugs were not assessed in non-HoFH patients, and their effects on cardiovascular morbidity and mortality remain unknown. In addition, the cost effectiveness and safety of these treatments are inferior to LDL-apheresis and PCSK9 inhibitors, which may limit their future use.
Finally, liver transplantation is an effective, yet invasive, treatment for HoFH based on a small number of interventions . This option works by replacing dysfunctional LDL receptors with functional ones, leading to nearly normal LDL metabolism . Khalifeh et al  performed a successful liver transplantation to a HoFH patient, who was born to first-degree Lebanese cousins. Two of the most common complications following liver transplant are rejection and infection. Therefore, other treatments as stated above are now available which are more effective and less invasive.
7. THE NEED TO ESTABLISH A SAUDI FH REGISTRY
The World Health Organization (WHO) defined patient registry as a collection of documents containing intrinsic/specific information about the state of health of individuals arranged in a systematic and comprehensive way, in order to serve a predetermined scientific, clinical or policy purpose . The relatively low reporting of FH with the higher prevalence of CVD in Saudi Arabia  prompted us to initiate a patient database as a preventative measure toward reducing the incidence of CVD.
The FH registry aims toward raising awareness of FH among the population with the hope of decreasing the consequences of this condition in the long term and eventually lowering morbidity and mortality. Determining the exact cause and pathogenicity of the condition aids in preventing the complications. Moreover, understanding the genetic predisposition of such disorder provides an early intervention, thus early management. Furthermore, it will help determine the most common known mutation\variant among the Saudi population and identify population-specific novel mutations aiding future rapid molecular diagnosis. The database will allow different users to perform entries, including clinical and genetic service providers, to have a centralised system for ease of access from any location. Distinct privileges will be assigned to control access, yet the system will allow specific tasks related to education to be executed by general users. Researchers and other third parties, such as other registries, can access de-identified data through the consultative body, research ethics committees and the data stewards.
The careful documentation of FH cases will allow for statically-improved studies, scientific collaborations, meta-analytical studies, and international clinical trials to take place in Saudi Arabia. The outcome from this registry should enable studies of the natural history of the disease within Saudi individuals, provide evidence for therapies and suggest methods for health economic refinements.
8. BUILDING THE SAUDI GENETIC DATABASE
There is no standard basis for establishing FH registries since it is relatively an emerging field and each culture is unique. The International FH foundation lately set-up a very inclusive, well-designed, consensual guidance for FH managing based on an international viewpoint . This can be a convenient guidance for the promotion of a patient database at all stages as a first step towards initiating a full registry that can benefit more parties.
Targeted, universal, and opportunistic screening strategies using the DLCN  or Simon-Broome  criteria will be used to identify index FH cases in the Saudi population. Both can be an appropriate standard for initial clinical FH detection and can be compared and evaluated in a 5-year period for efficiency within the Saudi population. In this way, suspected cases of FH could be referred to lipid specialists if available locally. Genotype and phenotype assessment are ideal for all FH cases, but the phenotype test should be sufficient even if genotype testing are not feasible. Data collection will be performed at various sites in the country, mainly from lipid clinics and laboratories where genetic results are reported. Creating a web-based platforms will enable the Saudi FH patient database to be very interactive and accessible from different locations, with multiple-level private access for a broad range of users. In order to cover more FH cases from the various region, additional pages can be added to the registry with user groups being assigned appropriate upload and access privileges. Thus, many general practices regardless of their location can also contribute to the FH patient database. General practitioner (GP) entries will be of special interest since each GP will examine a spectrum of FH cases and by virtue of such service, the distant communication between patients and their practitioners will be shortened. The Saudi FH Database will be coordinated centrally in a manner consistent with accesses to cascade screening in order to ensure authenticity and accuracy of collected data. The minimum common data gathered for the Saudi FH Database will be guided by clinical and laboratory experts. Connection with other databases or registries and clinical cohort, both within Gulf region and worldwide will also ensure harmonisation of the data items.
9. GENETIC TESTING AND CASCADE SCREENING
Genetic testing is critical for building the FH registry, as it increases the sensitivity of FH screening and identifies the underlying genotype of the population. Confirmation of FH diagnosis by genetic testing should be made after a referral from a lipid specialist or any equivalent. Screening for genetic mutations will include known FH genes (candidate genes) described above. If no mutations have been identified in these genes, a copy number variants search and whole-exome sequencing would be the next line of action. Cascade is the terminology describing the procedure where FH is explored in relatives of an FH case starting with the patient himself as an index case (the first individual with the clinical presentation of a disease in a pedigree) and then “cascading” throughout the rest of the extended family . In cascade screening, first-, second-, and third-degree relatives, whether affected or not affected, should go through the test as they have 50%, 25% and 12.5% possibility of inheriting the mutation, respectively. Although HoFH can result from consanguineous breeding because of autozygosity, it can also arise from breeding between nonrelated HeFH individuals. Developing a database for such a high prevalent disease can highly improve the early detection of the disease. Furthermore, this project will support and justify universal screening of FH in children in Saudi Arabia (age range 2-9 years) as implemented in other countries.
The successful initiation of the FH registry relies on public awareness, starting with the families, physicians and government officials. Attention to the premature CVD risk associated with FH will eventually push for cascade screening. These objectives can be achieved by a strong pre-registry campaign (e.g. via the media) that could also eliminate cultural barriers hindering the establishment of a registry. This will also set the stage for the Gulf Countries Council (GCC) National FH registry and the regional Middle East and North Africa (MENA) FH registry in the long-term.
CONSENT FOR PUBLICATION
CONFLICT OF INTEREST
ZA and FA are sitting on the advisory board and delivering educational lectures for AMGEN and SANOFI pharmaceutical companies.
Dr Awan was supported by the Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia [Grant numbers: G-613-140-37]. Dr Alallaf was supported by the National Science, Technology, and Innovative Plan (MAARIFAH), Kingdom of Saudi Arabia [Grant numbers: 08-BIO34-10].
|||Brown MS, Goldstein JL. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man 1974; 185(4145): 61-3. Jul 5 [cited 2017 May 13]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/4366052
|||Innerarity TL, Weisgraber KH, Arnold KS, et al. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 1987; 84(19): 6919-23. [Internet].
|||Abifadel M, Varret M, Rabès J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34(2): 154-6. [Internet].
|||Garcia CK, Wilund K, Arca M, Zuliani G, Fellin R, Maioli M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein 2001.
|||Filigheddu F, Quagliarini F, Campagna F, et al. Prevalence and clinical features of heterozygous carriers of autosomal recessive hypercholesterolemia in Sardinia. Atherosclerosis 2009; 207(1): 162-7.
|||Nakane S, Matsumoto S, Takakura Y, Hashida M, Sezaki H. The accumulation mechanism of cationic mitomycin C-dextran conjugates in the liver: in-vivo cellular localization and in-vitro interaction with hepatocytes. J Pharm Pharmacol 1988; 40(1): 1-6. Jan [cited 2017 May 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2452868|
|||Kwiterovich PO Jr, Bachorik PS, Smith HH, et al. Hyperapobetalipoproteinaemia in two families with xanthomas and phytosterolaemia. Lancet 1981; 1(8218): 466-9.
|||Yamamoto T, Yamashita T. Low-density lipoprotein apheresis using the Liposorber system: features of the system and clinical benefits. Ther Apher 1998; 2(1): 25-30. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10227785
|||Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28(1): 253-9. Jul [cited 2017 May 13]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8752822|
|||Goldstein JL, Brown MS. Familial hypercholesterolemia: a genetic receptor disease. Hosp Pract (Off Ed) 1985; 20(11): 35-41-45-6. Nov 15 [cited 2017 May 14]. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3932389
|||Hennekens CH. Risk factors for coronary heart disease in women. Cardiol Clin [Internet] 1998; 16(1): 1-8. Feb [cited 2017 May 13]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9507775
|||Henderson R, O’Kane M, McGilligan V, Watterson S. The genetics and screening of familial hypercholesterolaemia. J Biomed Sci 2016; 23: 39. [Internet].
|||Scientific Steering Committe on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991; 303(October): 893-6.
|||Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society Eur Heart J [Internet] 2013; 34(45): 3478-568. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23956253|
|||Bruckert E. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement. Atheroscler Suppl 2014; 15(2): 26-32. [Internet].
|||Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J [Internet] 2010; 31(23): 2844-97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20965889|
|||Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science [Internet] 1986; 232(4746): 34-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3513311
|||Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 2008; 72(Pt 4): 485-98.
|||Fokkema IF, den Dunnen JT, Taschner PE. LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. Hum Mutat 2005; 26(2): 63-8.
|||Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004; 160(5): 421-9.
|||Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 1986; 78(5): 1410-4.
|||Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review. Am J Epidemiol [Internet] 2004; 160(5): 407-27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15321837
|||Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2003; 23(11): 1963-70.
|||Awan Z, Choi HY, Stitziel N, et al. APOE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis 2013; 231(2): 218-22.
|||Marduel M, Ouguerram K, Serre V, et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. Hum Mutat 2013; 34(1): 83-7.
|||Joseph L. The metabolic and molecular bases of inherited disease Familial hypercholesterolemia New York: In: McGraw-Hill McGraw-Hill. 2001; pp. 2863-3776.|
|||Goldberg AC, Robinson JG, Cromwell WC, Ross JL, Ziajka PE. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5(3)(Suppl.): S46-51.
|||Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J 2015; 36(9): 560-5.
|||Moorjani S, Roy M, Gagné C, et al. Homozygous familial hypercholesterolemia among French Canadians in Québec Province. Arteriosclerosis 1989; 9(2): 211-6.
|||Seftel HC, Baker SG, Jenkins T, Mendelsohn D. Prevalence of familial hypercholesterolemia in Johannesburg Jews. Am J Med Genet 1989; 34(4): 545-7.
|||Seftel HC, Baker SG, Sandler MP, et al. A host of hypercholesterolaemic homozygotes in South Africa. BMJ 1980; 281(6241): 633-6. [Internet].
|||Abifadel M, Rabès JP, Jambart S, et al. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum Mutat 2009; 30(7): E682-91.
|||Rubinsztein DC, van der Westhuyzen DR, Coetzee GA. Monogenic primary hypercholesterolaemia in South Africa. S Afr Med J 1994; 84(6): 339-44.
|||Slimane MN, Pousse H, Maatoug F, Hammami M, Ben Farhat MH. Phenotypic expression of familial hypercholesterolaemia in central and southern Tunisia. Atherosclerosis 1993; 104(1-2): 153-8.
|||Gudnason V, Sigurdsson G, Nissen H, Humphries SE. Common founder mutation in the LDL receptor gene causing familial hypercholesterolaemia in the Icelandic population. Hum Mutat 1997; 10(1): 36-44.
|||Hyttinen L, Autti T, Rauma S, Soljanlahti S, Vuorio AF, Strandberg TE. White matter hyperintensities on T2-weighted MRI images among DNA-verified older familial hypercholesterolemia patients. Acta Radiol 2009; 50(3): 320-6.
|||Fahed AC, Safa RM, Haddad FF, et al. Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. Mol Genet Metab 2011; 102(2): 181-8.
|||Alharbi KK, Kashour TS, Al-Hussaini W, Al-Nbaheen M, Mohamed S, Hasanato RM, et al. Association of angiotensin converting enzyme gene insertion/deletion polymorphism and familial hypercholesterolemia in the Saudi population Lipids Health Dis [Internet] 2013; 12(1): 177. Dec 1 [cited 2017 May 14] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24289455|
|||Al-Allaf FA, Athar M, Abduljaleel Z, Bouazzaoui A, Taher MM, Own R, et al. Identification of a novel nonsense variant c1332dup, p(D445*) in the LDLR gene that causes familial hypercholesterolemia Hum genome Var. 2014. 1:14021|
|||Alharbi KK, Kashour TS, Al-Hussaini W, et al. Screening for genetic mutations in LDLR gene with familial hypercholesterolemia patients in the Saudi population. Acta Biochim Pol 2015; 62(3): 559-62.
|||Al-Allaf FA, Athar M, Abduljaleel Z, et al. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease. Gene 2015; 565(1): 76-84.
|||Al-Allaf FA, Alashwal A, Abduljaleel Z, Taher MM, Siddiqui SS, Bouazzaoui A. Identification of a recurrent frameshift mutation at the LDLR exon 14 (c2027delG, p(G676Afs*33)) causing familial hypercholesterolemia in Saudi Arab homozygous children Genomics [Internet] 2016; 107(1): 24-32. Jan [cited 2017 May 14] Available from: http://www.ncbi.nlm.nih.gov/pubmed/26688439|
|||Al-Allaf FA, Alashwal A, Abduljaleel Z, Taher MM, Bouazzaoui A, Abalkhail H, et al. Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient. Acta Biochim Pol 2016.
|||Pahan K. Lipid-lowering drugs Cell Mol Life Sci [Internet] 2006. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16568248
|||Familial hypercholesterolaemia: identification and management | Guidance and guidelines | NICE [cited 2017 May 14] Available from: https://www.nice.org.uk/guidance/cg71|
|||Couture P, Lamarche B. Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyond. Curr Opin Lipidol 2013; 24(3): 227-32. [Internet].
|||Mullard A. 2013 FDA drug approvals. Nat Rev Drug Discov 2014; 13(2): 85-9. [Internet].
|||Tonkin AM, Watts GF, Blom D, Rader D, Stein E. Into the future: diversifying lipid management Lancet (London, England) [Internet] 2012; 380(9858): 1971-4. Dec 8 [cited 2017 May 14]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23141810|
|||Page MM, Ekinci EI, Jones RM, Angus PW, Gow PJ, O’Brien RC. Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. Intern Med J 2014; 44(6): 601-4.
|||Khalifeh M, Faraj W, Heaton N, Rela M, Sharara AI. Successful living-related liver transplantation for familial hypercholesterolemia in the Middle East. Transpl Int 2005; 17(11): 735-9.
|||Taylan C, Schlune A, Meissner T. A??ukaitis K, Udink ten Cate FEA, Weber LT. Disease control via intensified lipoprotein apheresis in three siblings with familial hypercholesterolemia. J Clin Lipidol 2016.
|||Report on the state of the art of rare disease activities in europe of the european union committee of experts on rare diseases part iii : activities in eu member states and other european countries [cited 2017 may 14] 2011. Available from: http://ec.europa.eu/health//sites/health/files/rare_diseases/docs/eucerd2011_report_state_of_art_raredis_activities_3.pdf|
|||Bamimore MA, Zaid A, Banerjee Y, et al. Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry. J Clin Lipidol 2015; 9(2): 187-94.
|||Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation 2014.
|||Franke JG, Lansberg PJ. Dutch national screening and disease management program for Familial Hypercholesterolemia (FH) – A model for Saudi Arabia? J Saudi Hear Assoc [Internet] 2009 Oct [cited 2017 May 14] 2009; 21(4): 259-60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23960585|